The University of Osaka · 의학
마사키 교수의 연구실은 식도암 및 대장암의 전이 메커니즘과 치료 저항성의 분자 기전을 중심으로 연구를 진행하고 있습니다. 특히 화학요법에 대한 민감도를 조절하는 단백질(MRP2)과 전이성 대장암에서의 유전자 발현 변화를 분석함으로써, 치료 전략 개선에 기여하고자 합니다. 또한 신규 항암제의 유효성과 내성 메커니즘에 대한 기초 연구도 병행하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Our data suggested that MRP2 is one of molecules, which regulate the sensitivity to chemotherapy including CDDP in advanced ESCC patients.
DCF was tolerable and effective for advanced and recurrent ESCC. Such findings might encourage a change in the treatment strategy for ESCC.
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTProcarboxypeptidase A-S6.* Further Studies of its Isolation and PropertiesMakoto Yamasaki, James R. Brown, David J. Cox, Roderick N. Greenshields, Roger D. Wade, and Hans NeurathCite this: Biochemistry 1963, 2, 4, 859–866Publication Date (Print):July 1, 1963Publication History Published online1 May 2002Published inissue 1 July 1963https://pubs.acs.org/doi/10.1021/bi00904a039https://doi.org/10.1021/bi00904a039research-articleACS PublicationsRequest reus
The major cause of death in colorectal cancer is related to liver metastasis. Although the metastatic process has been well studied, many aspects of the molecular genetic basis of metastasis remain unclear. Elucidation of the molecular nature of liver metastasis is urgent to improve the outcome of colorectal cancer. We analyzed the chronological gene expression profiles of 104 colorectal samples corresponding to oncogenic development including normal mucosa, localized and metastasized primary tu
The LN response to NACT predicted long-term survival more precisely than the PT response in patients with metastatic EC.
